TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1198232
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin after amniotomy
Study: 23221898
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with sodium valproate
Study: 23221898
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) without sodium valproate
Study: 10815116
Drug: Imipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (up to 300 mg/d)
Study: 8839505
Drug: High-fruit and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fruit and -vegetable diets (approximately 16 mg/d carotenoids)
Study: 8839505
Drug: High-carotenoid diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carotenoid diet with additional broccoli (205 g/d) for 5 days
Study: 1530752
Drug: Deep anesthesia
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep anesthesia with high doses of sufentanil
Study: 1530752
Drug: Lighter anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lighter anesthesia with halothane and morphine
Study: 6331157
Drug: Enalapril (MK-421,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (MK-421, 10 to 20 mg bid)
Study: 6331157
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 to 50 mg bid)
Study: 6331157
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (MK-421 + HCTZ)
Study: 25945019
Drug: 14 d
Normalized name: PEG-14 dimethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 d moxifloxacin‐based sequential therapy (MOX‐ST group)
Study: 25945019
Drug: 14 d
Normalized name: PEG-14 dimethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 d clarithromycin‐based sequential therapy (CLA‐ST group)
Study: 17075320
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (29 patients)
Study: 10848740
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 microg g‐1) applied immediately before irradiation
Study: 10848740
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 microg g‐1) applied immediately before irradiation
Study: 1563426
Drug: Diluted iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted iodine solution or barium suspension
Study: 27663358
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid prescription
Study: 22589423
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg transdermal nicotine
Study: 6489697
Drug: HCl control
Normalized name: DIETHYLPROPION HYDROCHLORIDE 75 mg ORAL TABLET [Diethylpropion HCl Controlled-Release]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCl control solution (200 ml of 100 mM HCl)
Study: 29972001
Drug: RT and
Normalized name: Comfort and Ease KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT and intradermal needling (group A)
Study: 22682750
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of neo-adjuvant androgen deprivation (NAD) before radiation therapy (RT)
Study: 22682750
Drug: 8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of neo-adjuvant androgen deprivation (NAD) before radiation therapy (RT)
Study: 22682750
Drug: Neo-adjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant androgen deprivation (NAD) in addition to radiation therapy
Study: 16048922
Drug: Rifampin orally
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2 weeks
Study: 3072420
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg captopril once daily
Study: 3072420
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg captopril twice daily
Study: 3072420
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril three times daily
Study: 21354935
Drug: Pelvic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pelvic methotrexate (MTX) injection via the posterior fornix + mifepristone + traditional Chinese medicine
Study: 21354935
Drug: Intramuscular MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular MTX injection + mifepristone + traditional Chinese medicine
Study: 21354935
Drug: Mifepristone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone + traditional Chinese medicine
Study: 19365399
Drug: escitalopram (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram (serotonin reuptake inhibitor)
Study: 19365399
Drug: nortriptyline (norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: nortriptyline (norepinephrine reuptake inhibitor)
Study: 17455472
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SF)
Study: 9757602
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (21.0 g NaCl)
Study: 9757602
Drug: Normal-salt diet
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal-salt diet (approximately 5.6 g NaCl)
Study: 7831452
Drug: Novel nonsedating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel nonsedating compound (dose not specified)
Study: 3242576
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (ACE inhibitors, calcium antagonists, direct vasodilators, alpha‐adrenoceptor blocker, beta‐adrenoceptor blocker)
Study: 3242576
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents (four types)
Study: 30263038
Drug: Green cardamom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green cardamom (GC) - 2 capsules of 500 mg three times per day for 3 months
Study: 15590252
Drug: Alfentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (1 mg)
Study: 7490173
Drug: ST200 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST200 at 1 g/die
Study: 7490173
Drug: ST200 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST200 at 0.5 g/die
Study: 2208182
Drug: CQA 206‐291
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQA 206‐291 (5‐30 mg/day)
Study: 517068
Drug: Other marketed
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other marketed bronchodilators (clenbuterol, epinephrine, fenoterol, hexoprenaline, isoprenaline, metaproterenol, reproterol, salbutamol)
Study: 517068
Drug: Terbutaline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline and other adrenoceptor agonists
Study: 517068
Drug: Combined substance
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined substance drug
Study: 25669730
Drug: Eltoprazine 5
Normalized name: Eltoprazine
DrugBank: Eltoprazine (DB12883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltoprazine 5 mg
Study: 25669730
Drug: Eltoprazine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltoprazine 7.5 mg
Study: 22424441
Drug: Dexamethasone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.0 mg)
Study: 8690814
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron (oral and intravenous)
Study: 1947367
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg tds) for 7 days
Study: 1947367
Drug: Amoxycillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (500 mg tds) for 7 days
Study: 6361318
Drug: KS-R1 (ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: KS-R1 (ampicillin rectal suppository) at a dose of 125 mg X 4/day for 7 days
Study: 6361318
Drug: Oral form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral form of ampicillin (ABPC) at the same dosage of 125 mg X 4/day for 7 days
Study: 6361318
Drug: KS-R1 (ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: KS-R1 (ampicillin rectal suppository)
Study: 6361318
Drug: Oral form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral form of ampicillin (ABPC)
Study: 28986670
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) administered intravenously for three consecutive days
Study: 28986670
Drug: Methylprednisolone administered
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone administered intravenously for three consecutive days
Study: 28986670
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment (>3 days)
Study: 20406223
Drug: Levofloxacin 1500
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 1500 mg
Study: 15102866
Drug: Levofloxacin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (various doses)
Study: 15102866
Drug: Levofloxacin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (1500 mg)
Study: 12066701
Drug: Excite dual‐cured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excite dual‐cured bonding agent self‐activated by an experimental microbrush in combination with MultiLink resin cement
Study: 12066701
Drug: Excite light‐cured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excite light‐cured bonding agent in combination with Variolink II resin cement
Study: 12066701
Drug: One‐step bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐step bonding system in combination with Dual Link resin cement
Study: 16039
Drug: 3 to
Normalized name: Melquin-3 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 6 mg lorazepam daily for four weeks
Study: 29670416
Drug: Intravenous Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Morphine
Study: 8519045
Drug: Probucol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (750 mg or 1000 mg daily)
Study: 8519045
Drug: Dipyridamole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (150 mg daily)
Study: 29847470
Drug: 8% topical
Normalized name: BPO 8% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% topical capsaicin patch
Study: 23075701
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice a day for 7 days (group A)
Study: 23075701
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg twice a day for 7 days (group B)
Study: 23075701
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice a day for 3 days each week for 2 weeks (group C)
Study: 12687927
Drug: Drug I
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug I (propafenone, sotalol, disopyramide)
Study: 12687927
Drug: Drug II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug II (second antiarrhythmic agent)
Study: 12687927
Drug: Drug III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug III (amiodarone)
Study: 12687927
Drug: Long-term amiodarone
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term amiodarone treatment
Study: 10419086
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil capsules (1.5-1.8 g DHA/d)
Study: 10419086
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil capsules (2 months)
Study: 10419086
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil capsules (2 months)
Study: 7539874
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin therapy
Study: 2193119
Drug: 12-week chemohormonal
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week chemohormonal treatment (CMFVP plus AT)
Study: 2193119
Drug: 36-week chemohormonal
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 36-week chemohormonal treatment (CMFVP)
Study: 4935627
Drug: Glycyrrhizinic-acid-reduced liquorice
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizinic-acid-reduced liquorice 760 mg thrice daily for six weeks
Study: 28234199
Drug: In-person or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person or Internet formats of administration for SES-SFP with men
Study: 28234199
Drug: In-person or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person or Internet formats of administration for SES-SFV with women
Study: 22089991
Drug: Conventional palpation-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional palpation-guided anatomic landmark injection
Study: 19558483
Drug: Manual oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual oral brushing plus 0.12% chlorhexidine oral rinse administered twice per day
Study: 19558483
Drug: Daily manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily manual oral brushing and upright feeding positioning
Study: 11231036
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) at a frequency of 0.2 Hz and intensity of 90% of motor threshold, delivered in four daily sessions with a train of 70 stimuli over 350 s
Study: 9406983
Drug: Atenolol 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 12.5 mg
Study: 9406983
Drug: Atenolol 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 37.5 mg
Study: 8218987
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 0.2 micrograms/kg ceruletide
Study: 3619095
Drug: 0.86 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.86 mg/kg nalbuphine
Study: 3619095
Drug: 0.17 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.17 mg/kg butorphanol
Study: 29048132
Drug: US-guided rhomboid
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided rhomboid major muscle injection
Study: 29048132
Drug: US-guided trapezius
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided trapezius muscle injection
Study: 23406268
Drug: 4 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implants
Study: 23406268
Drug: 6 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 implants
Study: 15331798
Drug: Pexelizumab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab (bolus and infusion)
Study: 15331798
Drug: Pexelizumab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab (bolus plus infusion)
Study: 16960923
Drug: infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infliximab 5 mg/kg
Study: 11410193
Drug: infliximab 10
Normalized name: infliximab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: infliximab 10 mg/kg
Study: 9243353
Drug: Desmethylselegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmethylselegiline (10 mg)
Study: 31755599
Drug: Deep Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Brain Stimulation (DBS) of the STN combined with best medical treatment
Study: 25595527
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (coronary angiography performed) - 182 patients
Study: 25595527
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (no coronary angiography) - 131 patients
Study: 21367726
Drug: 23vP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vP administered after priming with 2 doses of PCV7
Study: 21367726
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PCV7
Study: 15449741
Drug: TIVA Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIVA Propofol (6 mg/kg/h infusion)
Study: 11445795
Drug: Behavioral, family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral, family-based treatment
Study: 11445795
Drug: Parental involvement
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental involvement in treatment
Study: 22232050
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (15 mg per day)
Study: 7936334
Drug: FTTCA (Centella
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTTCA (Centella asiatica) 30 mg bid
Study: 7936334
Drug: FTTCA (Centella
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTTCA (Centella asiatica) 60 mg bid
Study: 26381165
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin alone
Study: 26381165
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg piragliatin alone
Study: 26381165
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin and 100 mg piragliatin together
Study: 24452825
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy with adjunctive systemic amoxicillin and metronidazole (n=19)
Study: 24452825
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (both groups)
Study: 22673159
Drug: Oral debriefing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral debriefing alone
Study: 20829150
Drug: Buccal envelope
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal envelope flap (control)
Study: 18164452
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for chronic low back pain; specific dosage and duration not mentioned.
Study: 15880022
Drug: Everolimus (Certican)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (Certican) in combination with reduced-exposure cyclosporine (CsA)
Study: 12598264
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus saline (MS; n = 114)
Study: 12598264
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus ketamine (MK; n = 131)
Study: 10367600
Drug: Perindopril (PER),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (PER), 2 mg once daily
Study: 10367600
Drug: Captopril (CAP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (CAP), 6.25 mg t.i.d.
Study: 1855277
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg prednimustine
Study: 29389835
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg (oral) SAL
Study: 29389835
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg (inhaled) SAL
Study: 25412911
Drug: Hormonal treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal treatment, Radiotherapy, Operation
Study: 12810176
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 20 mg weekly for 84 days
Study: 12810176
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 2.5 mg daily for 84 days
Study: 12810176
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose 130 mg or less
Study: 12810176
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 168 days
Study: 10589647
Drug: IV amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amino acid mixture, 126 mL/h
Study: 16415516
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution
Study: 1817629
Drug: Diamorphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 5 mg in 0.9% sodium chloride 8 ml
Study: 1817629
Drug: Diamorphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 5 mg in 0.9% sodium chloride 8 ml with 1:200,000 adrenaline
Study: 1817629
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine 8 ml
Study: 7172717
Drug: Topical 2.5%
Normalized name: menthol topical 2.5% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2.5% phenylephrine hydrochloride
Study: 30652422
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 8-10 mg/kg of body weight per day
Study: 28248693
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Calcium (CA)
Study: 27154593
Drug: Avoralstat 250
Normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat 250 mg single dose
Study: 27154593
Drug: Avoralstat 800
Normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat 800 mg multiple doses (q8 h for up to 7 days)
Study: 27154593
Drug: Avoralstat 2400
Normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat 2400 mg/day multiple doses
Study: 27154593
Drug: Avoralstat (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat (doses ≥400 mg q8 h)